• The company demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026.
  • At the European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, CEO Dr. Sudhir Srivastava performed a robotic-assisted atrial septal defect procedure on a patient approximately 7,500 miles away in Bengaluru, India.
  • Four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric and gynecological procedures.
  • The company reported 205 telesurgeries performed with the SSi Mantra system as of October 23, 2026, including cardiac procedures.
  • The demonstrations highlight the potential for remote robotic surgery to extend specialist expertise beyond major medical centers, although widespread adoption depends on clinical validation, connectivity and regulatory requirements.
  • SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027; the timeline remains subject to the FDA’s review.

The demonstrations featured the company’s SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console. At the 40th European Association for Cardio-Thoracic Surgery (“EACTS”) annual meeting in Barcelona, SS Innovations Chairman and Chief Executive Officer Dr. Sudhir Srivastava remotely performed an atrial septal defect procedure on a patient at…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.